398 related articles for article (PubMed ID: 34978092)
21. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in clinical trials targeting the kynurenine pathway.
Pires AS; Sundaram G; Heng B; Krishnamurthy S; Brew BJ; Guillemin GJ
Pharmacol Ther; 2022 Aug; 236():108055. PubMed ID: 34929198
[TBL] [Abstract][Full Text] [Related]
23. A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.
Orsatti L; Speziale R; Orsale MV; Caretti F; Veneziano M; Zini M; Monteagudo E; Lyons K; Beconi M; Chan K; Herbst T; Toledo-Sherman L; Munoz-Sanjuan I; Bonelli F; Dominguez C
J Pharm Biomed Anal; 2015 Mar; 107():426-31. PubMed ID: 25668794
[TBL] [Abstract][Full Text] [Related]
24. Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study.
Kruse JL; Cho JH; Olmstead R; Hwang L; Faull K; Eisenberger NI; Irwin MR
Psychoneuroendocrinology; 2019 Nov; 109():104371. PubMed ID: 31325802
[TBL] [Abstract][Full Text] [Related]
25. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
26. Kynurenine pathway in depression: A systematic review and meta-analysis.
Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
[TBL] [Abstract][Full Text] [Related]
27. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
28. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
29. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.
Brum M; Nieberler M; Kehrwald C; Knopf K; Brunkhorst-Kanaan N; Etyemez S; Allers KA; Bittner RA; Slattery DA; McNeill RV; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2023; 24(7):564-577. PubMed ID: 36648064
[TBL] [Abstract][Full Text] [Related]
30. The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?
Joisten N; Ruas JL; Braidy N; Guillemin GJ; Zimmer P
Trends Mol Med; 2021 Oct; 27(10):946-954. PubMed ID: 34373202
[TBL] [Abstract][Full Text] [Related]
31. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus.
Eryavuz Onmaz D; Tezcan D; Yilmaz S; Onmaz M; Unlu A
Amino Acids; 2023 Dec; 55(12):1937-1947. PubMed ID: 37925676
[TBL] [Abstract][Full Text] [Related]
32. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Ciapała K; Mika J; Rojewska E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
[TBL] [Abstract][Full Text] [Related]
33. Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies.
Arnone D; Saraykar S; Salem H; Teixeira AL; Dantzer R; Selvaraj S
Neurosci Biobehav Rev; 2018 Sep; 92():477-485. PubMed ID: 29940237
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the antioxidant properties of tryptophan and its metabolites in in vitro assay.
Nayak BN; Buttar HS
J Complement Integr Med; 2016 Jun; 13(2):129-36. PubMed ID: 26641976
[TBL] [Abstract][Full Text] [Related]
35. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.
Sanni LA; Thomas SR; Tattam BN; Moore DE; Chaudhri G; Stocker R; Hunt NH
Am J Pathol; 1998 Feb; 152(2):611-9. PubMed ID: 9466588
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis.
Cao B; Chen Y; Ren Z; Pan Z; McIntyre RS; Wang D
Neurosci Biobehav Rev; 2021 Apr; 123():203-214. PubMed ID: 33513412
[TBL] [Abstract][Full Text] [Related]
37. Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training.
Joisten N; Kummerhoff F; Koliamitra C; Schenk A; Walzik D; Hardt L; Knoop A; Thevis M; Kiesl D; Metcalfe AJ; Bloch W; Zimmer P
Exerc Immunol Rev; 2020; 26():24-42. PubMed ID: 32139353
[TBL] [Abstract][Full Text] [Related]
38. Central kynurenine pathway shift with age in women.
de Bie J; Guest J; Guillemin GJ; Grant R
J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
[TBL] [Abstract][Full Text] [Related]
39. An expanding range of targets for kynurenine metabolites of tryptophan.
Stone TW; Stoy N; Darlington LG
Trends Pharmacol Sci; 2013 Feb; 34(2):136-43. PubMed ID: 23123095
[TBL] [Abstract][Full Text] [Related]
40. Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids.
Yan J; Kothur K; Innes EA; Han VX; Jones HF; Patel S; Tsang E; Webster R; Gupta S; Troedson C; Menezes MP; Antony J; Ardern-Holmes S; Tantsis E; Mohammad S; Wienholt L; Pires AS; Heng B; Guillemin GJ; Guller A; Gill D; Bandodkar S; Dale RC
EBioMedicine; 2022 Oct; 84():104280. PubMed ID: 36174397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
